Type 2 Diabetes (T2D): Evaluating Emerging Insulin Therapies – QI&CPD – Category 2

The availability of new insulin therapies has led to new opportunities in the management of type 2 diabetes (T2D), with insulin analogues and combinations demonstrating evidence-based improvements in hypoglycaemia, weight change, and cardiovascular risk factors/outcomes. This module examines two newer insulin therapies: the first is premixed basal insulin plus rapid acting insulin (RAI combination), and the second is single-injection fixed-ratio combinations of basal insulin plus glucagon-like peptide-1 (GLP-1) receptor agonist (Note that these are not yet available in Australia). As hypoglycaemia is a major obstacle for patients with T2D to achieve glycaemic targets, this module will focus on the effects of newer insulin therapies on hypoglycaemia.